Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858221 · ClinicalTrials.gov registry record
Association of Genes to Resistance to Weight Loss in Obese Patients
A clinical trial of Obesity and Metabolic Syndrome, sponsored by Interleukin Genetics.
- Completed
- Registry status
- 824
- Enrollment target
- 1
- Study location
NCT00858221 is a study of Obesity and Metabolic Syndrome that has completed, run by Interleukin Genetics. The registered enrollment target is 824 participants, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00858221, a study of Obesity and Metabolic Syndrome, has completed, sponsored by Interleukin Genetics.
- COMPLETED
- Registry status
- 824 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to determine whether variations in the perilipin, and several other, genes would be a useful tool for physicians who are caring for morbidly obese patients to guide therapy. The main hypotheses to be tested is that sequence variations (polymorphisms) in the perilipin gene and several other obesity-related genes are associated with resistance to weight loss for obese individuals on energy restricted diets, potentially playing a role in the development of obesity related complications.
Conditions Studied
Study Locations (1)
Pennsylvania
- Geisinger Health System - Danville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 824 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00858221
The ClinicalTrials.gov registry entry for NCT00858221 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 824 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The listed sponsor is Interleukin Genetics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 0 interventions.
NCT00858221 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00858221 about?
NCT00858221 is a clinical study titled "Association of Genes to Resistance to Weight Loss in Obese Patients". The overall goal of this study is to determine whether variations in the perilipin, and several other, genes would be a useful tool for physicians who are caring for morbidly obese patients to guide therapy. The main hypotheses to be tested is that sequence variations (polymorphisms) in the perilip...
What is the current status of trial NCT00858221?
This trial is currently completed. The enrollment target is 824 participants. The study started on 2008-08. Estimated completion is 2009-07.
What conditions does trial NCT00858221 study?
This clinical trial studies the following conditions: Obesity, Metabolic Syndrome, Dyslipidemia.
Who is sponsoring clinical trial NCT00858221?
This trial is sponsored by Interleukin Genetics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00858221 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.